Literature DB >> 21477143

The availability and age-appropriateness of medicines authorized for children in The Netherlands.

Diana A van Riet-Nales1, Karin E de Jager, Alfred F A M Schobben, Toine C G Egberts, Carin M A Rademaker.   

Abstract

AIM: To study the number of medicines and active chemical entities that are authorized and commercially available for children in the Netherlands and to evaluate the age-appropriateness of the available paediatric medicines.
METHODS: The availability of paediatric medicines and active chemical entities was studied with the help of a Dutch medicines database and the Summary of Product Characteristics. Medicines were categorized with respect to their route of administration, type of oral dosage form and therapeutic category. The age-appropriateness was assessed on three aspects: dose capability, suitability of the dosage form and inclusion of potentially harmful excipients.
RESULTS: Three thousand five hundred and forty-two paediatric medicines containing 703 different active chemical entities were identified. This equalled half of all the medicines and chemical entities available for human use. The percentage of paediatric medicines increased with age and varied for the route of administration from 22% (dermal) to 81% (inhalation) and for the therapeutic category from 11% (uro-genital, sex hormones) to 89% (anti-parasites). The appropriateness of the paediatric medicines with respect to their authorization status, dose capability and dosage form increased with age from 27-88%. Fifty-two percent of all oral paediatric liquid formulations contained a potentially harmful excipient.
CONCLUSION: This study confirms the limited availability of paediatric medicines for a broad range of therapeutic areas and shows that paediatric medicines may not be age-appropriate, even if authorized. While confirming the need for a legislative incentive, the results also provide baseline information for an estimation of the effect of the European Paediatric Regulation in the near future.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21477143      PMCID: PMC3175516          DOI: 10.1111/j.1365-2125.2011.03982.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.

Authors:  A Ceci; M Felisi; M Catapano; P Baiardi; L Cipollina; S Ravera; S Bagnulo; S Reggio; G Rondini
Journal:  Eur J Clin Pharmacol       Date:  2002-09-25       Impact factor: 2.953

2.  Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.

Authors:  Komathi Balakrishnan; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2006-07-26       Impact factor: 4.335

3.  Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.

Authors:  Komathi Balakrishnan; Joanne Grieve; June Tordoff; Pauline Norris; David Reith
Journal:  J Clin Pharmacol       Date:  2006-09       Impact factor: 3.126

4.  Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.

Authors:  A Ceci; M Felisi; P Baiardi; F Bonifazi; M Catapano; C Giaquinto; A Nicolosi; M Sturkenboom; A Neubert; I Wong
Journal:  Eur J Clin Pharmacol       Date:  2006-10-05       Impact factor: 2.953

5.  Access to prescribing information for paediatric medicines in the USA: post-modernization.

Authors:  Larissa Young; Francis Lawes; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2008-12-10       Impact factor: 4.335

6.  Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients.

Authors:  Robert Cohen; France de La Rocque; Aurélie Lécuyer; Claudie Wollner; Marie Josée Bodin; Alain Wollner
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

Review 7.  Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: a systematic literature review.

Authors:  Diana A van Riet-Nales; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker
Journal:  Clin Ther       Date:  2010-05       Impact factor: 3.393

8.  Effect of the pediatric exclusivity provision on children's access to medicines.

Authors:  Joanne Grieve; June Tordoff; David Reith; Pauline Norris
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

9.  Minitablets: new modality to deliver medicines to preschool-aged children.

Authors:  Sarah A Thomson; Catherine Tuleu; Ian C K Wong; Simon Keady; Kendal G Pitt; Alastair G Sutcliffe
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

10.  Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: an industry perspective.

Authors:  Philippe Auby
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-12-08       Impact factor: 3.033

View more
  13 in total

1.  Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study.

Authors:  Laura Cuzzolin; Rocco Agostino
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

2.  Toxic excipients in medications for neonates in Brazil.

Authors:  Alcidésio Souza; Djanilson Santos; Said Fonseca; Marina Medeiros; Lívia Batista; Mark Turner; Helena Coelho
Journal:  Eur J Pediatr       Date:  2014-02-06       Impact factor: 3.183

3.  Development and evaluation of an assessment of the age-appropriateness/inappropriateness of formulations used in children.

Authors:  Jennifer C Duncan; Louise E Bracken; Anthony J Nunn; Matthew Peak; Mark A Turner
Journal:  Int J Clin Pharm       Date:  2022-10-08

4.  A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia.

Authors:  Inese Sviestina; Dzintars Mozgis
Journal:  Eur J Hosp Pharm       Date:  2017-03-03

5.  Hospitalised neonates in Estonia commonly receive potentially harmful excipients.

Authors:  Jana Lass; Kaisa Naelapää; Utpal Shah; Ruth Käär; Heili Varendi; Mark A Turner; Irja Lutsar
Journal:  BMC Pediatr       Date:  2012-08-29       Impact factor: 2.125

6.  Acceptability of different oral formulations in infants and preschool children.

Authors:  Diana A van Riet-Nales; Barbara J de Neef; Alfred F A M Schobben; José A Ferreira; Toine C G Egberts; Catharine M A Rademaker
Journal:  Arch Dis Child       Date:  2013-07-13       Impact factor: 3.791

7.  Availability of pediatric-evaluated formulations in Serbia.

Authors:  Bojana Božić; Sanja Stupar; Duško Stupar; Uroš Babić; Milica Bajčetić
Journal:  Indian J Pharmacol       Date:  2017 Mar-Apr       Impact factor: 1.200

8.  Suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups.

Authors:  Jaqueline Cristina da Silveira Xavier E Castro; Stephanie Ferreira Botelho; Taisa Roberta Lopes Machado; Maria Auxiliadora Parreiras Martins; Liliana Batista Vieira; Adriano Max Moreira Reis
Journal:  Einstein (Sao Paulo)       Date:  2018-11-08

9.  Oral medicines for children in the European paediatric investigation plans.

Authors:  Diana A van Riet-Nales; Erwin G A W Römkens; Agnes Saint-Raymond; Piotr Kozarewicz; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

Review 10.  Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.

Authors:  Diana A van Riet-Nales; Alfred F A M Schobben; Herman Vromans; Toine C G Egberts; Carin M A Rademaker
Journal:  Arch Dis Child       Date:  2016-03-15       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.